IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of UnitsBusiness Wire • 07/14/21
Independent Proxy Advisory Firms Recommend IMV Shareholders Vote for All Director Nominees at the Upcoming Annual General and Special MeetingBusiness Wire • 06/08/21
IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical PipelineBusiness Wire • 05/12/21
IMV Inc. to Announce First Quarter 2021 Results and Host a Conference Call and Webcast on May 12, 2021Business Wire • 04/29/21
IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual ConferenceBusiness Wire • 04/13/21
IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma PatientsBenzinga • 04/07/21
IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDABusiness Wire • 04/07/21
IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational ResultsBusiness Wire • 03/17/21
IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021Business Wire • 03/08/21
IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences ConferenceBusiness Wire • 03/01/21
Durable Clinical Benefits Induced by IMV's T Cell Therapy in Combination With Merck's Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual MeetingBusiness Wire • 12/06/20
IMV's Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian CancerBusiness Wire • 12/03/20